Biotech | February 27, 2022
HitGen completes research collaboration with MTPC
Collaboration with MTPC to discover novel hit compounds for multiple drug targets
Collaboration with MTPC to discover novel hit compounds for multiple drug targets
Cantex also plans to initiate Phase 2 clinical trials exploring the therapeutic effect of azeliragon in pancreatic and breast cancers.
N Yuvraj, Joint Secretary, Dept of Pharmaceuticals, Satish Reddy, Chairman, Dr Reddy’s Laboratories; Kiran Mazumdar Shaw, Executive Chairperson, Biocon Group; Sanjiv Navangul, MD & CEO, Bharat Serums and Vaccines and Shravil Patel, MD, Zydus Lifesciences discuss the way forward for the India pharma industry
Tamper evident caps with incorporated RFID technology offer a significant reduction in RFID implementation costs
Guy Villax was also involved with the EFCG and Rx-360 associations and contributed to legislation being passed on both sides of the Atlantic to fight fake medicines and to level the playing field for GMP manufacturing.
Keytruda plus Lenvima is also approved in the U.S. and Europe for the first-line treatment of adult patients with advanced RCC.
Boehringer Ingelheim plans to study this novel investigational therapy in patients with progressive fibrosing interstitial lung diseases
It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).
The facility is spread across 215000 sq. feet and provides super-speciality care
This policy will ensure multi-disciplinary collaboration, promote start-up culture and develop an innovation-led ecosystem at medical institutes across the country
Subscribe To Our Newsletter & Stay Updated
